Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees?
This week: COMPASS Pathways survives challenges to two of its patents covering Polymorph A; MindMed is granted a patent covering candyflipping; we look at whether psychedelics companies will protect access to abortions; and more…
Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix
This week: We’re launching an Opinions Column; How to Change Your Mind is coming to Netflix; and more…
Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design
This week: a new study from Yale finds efficacy in DMT for depression while skimping on set and setting; Cybin acquires Entheon’s Phase 1 DMT study; FDA snubs Mydecine’s Seamess Trial Design; and more…
Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs
This week: UK regulator denies coverage of Spravato for third time; Innerwell launches KAP offering; Canada allows BC to trial 3-year decrim. expirment; and more…
Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules
This week: we speak to Mydecine’s CEO about insider activity that wasn’t filed for two years; UC Davis receives $2.7m from NIDA; Oregon Health Authority adopts products, testing and training rules; and more…
Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings
This week: MAPS’ second Phase 3 study of MDMA-AT for PTSD is on schedule; Australia’s national science agency is exploring medicinal psychedelics; ‘death spiral financings’ arrive to the psychedelics space; and more…